Company intelligence / Profile preview

ParcelBio

San Francisco, California, United Statesparcelbio.com ↗

Ownership: Private
Employees: ~5
Development stage: Preclinical

Overview

ParcelBio is developing a proprietary platform for the programmable delivery of mRNA medicines, aiming to overcome key challenges in targeted RNA therapeutic delivery. The company’s technology, STAmP, seeks to enable safe and specific targeting of mRNA without nanoparticles. No clinical results have been published yet; the company appears preclinical with a focus on platform development.

Therapeutic areas: Other
Modalities: mRNA therapeutics (Ribonucleic acid medicines)
Industry: Biotech

Drug pipeline

1 asset

stabilized anti-CD19 CAR mRNA

Preclinical

Partnerships

Y Combinator (accelerator/funding partner)

Beyond the preview

Go deeper on ParcelBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ParcelBio.

Explore the full profile